BC Innovations | May 4, 2018
Targets & Mechanisms

Solid hopes for T cell bispecifics

As next-generation T cell bispecifics hit the clinic, demonstrating efficacy in solid tumors could earn them a place in the immuno-oncology tool kit alongside CAR T cells and checkpoint inhibitors. T cell bispecific antibodies bring...
BC Innovations | Oct 10, 2017
Distillery Therapeutics


INDICATION: Solid tumors Patient sample, cell culture, mouse and monkey studies suggest ERY974 , a bispecific antibody against CD3 and GPC3 , could help treat multiple types of GPC3-positive solid tumors. In tissue samples from patients with...
BC Extra | Oct 4, 2017
Preclinical News

Chugai team describes bispecific GPC3 antibody's efficacy

A study published Wednesday in Science Translational Medicine described a novel bispecific antibody that overcomes the "on-target, off-tumor" effects plaguing current cancer immunotherapies utilizing bispecific T-cell redirecting antibodies (TRAB). While the efficacy of current TRAB...
Items per page:
1 - 3 of 3